Harbour Capital Advisors, LLC Crinetics Pharmaceuticals, Inc. Transaction History
Harbour Capital Advisors, LLC
- $419 Million
- Q4 2024
A detailed history of Harbour Capital Advisors, LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Harbour Capital Advisors, LLC holds 4,550 shares of CRNX stock, worth $146,965. This represents 0.06% of its overall portfolio holdings.
Number of Shares
4,550
Previous 4,550
-0.0%
Holding current value
$146,965
Previous $232,000
-0.0%
% of portfolio
0.06%
Previous 0.06%
Shares
1 transactions
Others Institutions Holding CRNX
# of Institutions
254Shares Held
89.2MCall Options Held
26.1KPut Options Held
11.8K-
Vanguard Group Inc Valley Forge, PA9.09MShares$294 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA6.95MShares$225 Million0.07% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$201 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.14MShares$198 Million3.06% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.41MShares$175 Million0.03% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.74B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...